FDMT - 4DMT Announces Presentations at Clinical Trials at the Summit 2024 Meeting | Benzinga
EMERYVILLE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company)), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced presentations at the Clinical Trials at the Summit (CTS) Meeting in Park City, Utah on June 8, 2024.
CTS 2024 Meeting Presentation Details
| Panel: |
| Designing Registration Trials with the Latest FDA Guidance |
| Time: |
| 1:49-2:09 p.m. MDT |
| Panelist: |
| Robert Kim, M.D., Chief Medical Officer, 4DMT |
| Scientific Presentation: |
| 24-week Results from the Randomized Phase 2 Dose Expansion Stage of PRISM Trial Evaluating 4D-150 in High Need nAMD Patients |
| Session: |
| Gene Therapy and Optogenetics |
| Time: |